Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

STORY: Eli Lilly said Monday it will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and ... May 27, 2025 Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug Eli Lilly ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.